FASTResponder
Sternal Intraosseous (IO) Infusion System
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for emergency medical responders and hospitals. Their FASTResponder Sternal Intraosseous (IO) Infusion System is the first FDA-cleared IO system designed specifically for use in the sternum during adult and adolescent emergency intervention.
When normal peripheral intravenous access fails, FASTResponder Sternal helps emergency care providers—in a hospital or during pre-hospital response—quickly establish vascular access and administer emergency fluids and medications safely and effectively through the bone marrow of the manubrium. For over 10 years the product has been widely used in military markets because of its rugged construction and portability.
The Challenge
With 10 years of military success, Pyng Medical Corp. wanted to re-energize the product line, and keep it ahead of marketplace competitors.
How StarFish Helped
Working together, StarFish Medical and Pyng Medical Corp. engaged with key military and civilian customers and end-users to identify the strengths and weaknesses of the FAST1® product. The team visited various military installations with senior medical training officers and battlefield medics and spent time shadowing civilian ground and airborne ambulance teams in the field.
The Results
Updating the military device for civilian appeal makes the FASTResponder™ a more useful device on the battle field. Less needles with a mechanical redesign that shields them in a transparent plastic shell creates an easier to handle device and improves civilian end-user perceptions. Reducing the size, weight, appearance and the force required for insertion allowed a more intuitive and ergonomic product appropriate for all civilian providers. The original force to operate the device is reduced making it easier to use by all. Together, StarFish Medical and Pyng Medical Corp have taken the FASTResponder™ product through the requirements testing process.
FASTResponder™, Pyng Medical Corps. next generation Sternal IO Infusion device, received the CE Mark in Europe and is cleared by the United States Food and Drug Administration (FDA) for marketing in the United States. The FASTResponder™ was also cleared by Health Canada.
The FASTResponder™ product has received initial positive input from medical professionals for being easy to learn and easy to use. This feedback indicates the possibility of Pyng Intraosseous Infusion products being used in a wider range of applications and markets. This market expansion opportunity is anticipated to enhance Pyng Medical Corp sales potential moving forward and the company is increasing marketing activity.
Client: Pyng Medical